The extended-spectrum triazoles (voriconazole, posaconazole, and isavuconazole) share the same fundamental mechanism of action as the first-generation azoles fluconazole and itraconazole but differ in ways that produce clinically decisive differences in spectrum, pharmacokinetics, tolerability, and drug interaction potential. Understanding the shared mechanism alongside the structural modifications that distinguish the second-generation agents is essential for rational selection among them.
Mechanism of Action: CYP51 (Fungal Lanosterol 14-Alpha-Demethylase) Inhibition. All azole antifungals act by inhibiting fungal cytochrome P450 (CYP) enzyme 14-alpha-demethylase, encoded by the ERG11 (sterol 14-alpha-demethylase gene) in Candida species and the Cyp51A and Cyp51B genes in Aspergillus species. This enzyme, also designated CYP51 (fungal 14-alpha-sterol demethylase), catalyzes the oxidative removal of the 14-alpha-methyl group from lanosterol, an obligatory step in the biosynthetic pathway leading from lanosterol to ergosterol. When CYP51 is inhibited, lanosterol and other 14-alpha-methylated sterol intermediates accumulate in the fungal cell membrane at the expense of ergosterol. The resulting membrane lacks normal ergosterol content, disrupting membrane fluidity, the activity of membrane-embedded enzymes including chitin synthase and the proton-pumping adenosine triphosphatase (ATPase), and the integrity of cell wall biosynthetic processes that depend on ergosterol-rich membrane microdomains.1
The mechanism is fungistatic rather than fungicidal for most organisms, because ergosterol depletion impairs growth and division without producing the direct, rapid membrane disruption characteristic of the polyene antifungals. This distinction has practical consequences: fungistatic agents rely heavily on host immune function to achieve cure, which is why outcomes with azole monotherapy tend to be worse in profoundly immunocompromised patients than in those with intact immunity. An important exception is Candida species, where the accumulation of toxic methylated sterol intermediates may contribute additional membrane damage beyond simple ergosterol depletion, producing effects closer to fungicidal activity in some experimental models, though clinical azole therapy against candidiasis is still classified as fungistatic for the purposes of therapeutic decision-making.1
Structural Advances of the Second-Generation Agents. The first-generation triazoles fluconazole and itraconazole established the azole class as clinically central to antifungal therapy but revealed significant limitations. Fluconazole has a narrow spectrum, lacking reliable activity against Aspergillus species and many non-albicans Candida species. Itraconazole has erratic oral bioavailability, significant gastrointestinal (GI) absorption dependence on formulation and gastric acidity, and a complex drug interaction profile. The second-generation triazoles were developed with structural modifications to the azole scaffold, primarily extension of the side-chain substituents attached to the triazole-linked carbon, that increase binding affinity and steric fit for the CYP51 enzyme active site of mold pathogens, particularly Aspergillus fumigatus, the Mucorales (for isavuconazole), and the endemic dimorphic fungi. These structural changes also alter the interaction of the drug with human cytochrome P450 enzymes, with important consequences for drug-drug interaction profiles that differ meaningfully among the three agents.2
Overview of the Three Agents. Voriconazole, approved by the United States Food and Drug Administration (FDA) in 2002, became the standard of care for invasive aspergillosis based on its superior outcomes compared to amphotericin B deoxycholate (AmBd) in a landmark randomized trial. It offers broad mold coverage with a well-characterized oral bioavailability and is available in both oral and intravenous (IV) formulations, but is associated with significant hepatotoxicity, visual disturbances, and complex non-linear pharmacokinetics that necessitate therapeutic drug monitoring (TDM). Posaconazole, approved in 2006, is distinguished primarily by its role in antifungal prophylaxis in high-risk immunocompromised patients and by its activity against the Mucorales, an important gap in voriconazole spectrum. Isavuconazole, the most recently approved agent (2015), offers a more favorable tolerability profile and simpler pharmacokinetics than voriconazole, with equivalent clinical efficacy for invasive aspergillosis and Mucorales coverage comparable to posaconazole.2
All azoles are fungistatic, not fungicidal. In profoundly neutropenic or T-cell-depleted patients, azole therapy controls but does not eradicate infection; immune reconstitution is essential for cure. This is why antifungal therapy duration is prolonged until immunosuppression resolves in hematologic malignancy and transplant settings. The distinction is also the basis for combination strategies pairing azoles with echinocandins in some refractory cases, aiming for broader pharmacodynamic coverage.
Voriconazole remains the cornerstone of therapy for invasive aspergillosis and a first-line or important alternative agent for a range of other mold and yeast infections. Its clinical use is complicated by non-linear pharmacokinetics, significant interpatient pharmacokinetic variability driven by genetic polymorphism in the primary metabolizing enzyme, and a toxicity profile that requires systematic monitoring. Mastering voriconazole pharmacology is essential for any clinician managing immunocompromised patients.
Oral Bioavailability and Absorption. Voriconazole has excellent oral bioavailability of approximately 96% under fasting conditions in adults, which is one of its major advantages over itraconazole. The drug should be taken on an empty stomach because high-fat meals reduce absorption and decrease peak plasma concentrations (Cmax) by approximately 34% and area under the curve (AUC) by approximately 24%. This food-absorption interaction is clinically meaningful in inpatient settings where medication administration and meal timing are difficult to coordinate, and it is a practical source of subtherapeutic voriconazole concentrations even when doses appear appropriate. The oral tablets and suspension formulations are bioequivalent under fasting conditions. Intravenous voriconazole is formulated with sulfobutylether-beta-cyclodextrin (SBECD) as a solubilizing vehicle; SBECD accumulates in renal insufficiency and, while not directly nephrotoxic, is renally excreted and can reach concentrations of uncertain safety in patients with creatinine clearance (CrCl) below 50 mL/min, providing a rationale for switching to oral voriconazole when renal function declines during IV therapy.3
Distribution and Protein Binding. Voriconazole has a large volume of distribution (approximately 4.6 L/kg), reflecting extensive tissue penetration including the central nervous system (CNS). This property makes voriconazole the preferred agent for Aspergillus CNS infections, where adequate drug concentrations in brain tissue and cerebrospinal fluid (CSF) are critical. Protein binding is approximately 58%, lower than itraconazole (greater than 99%), which means a larger fraction of voriconazole circulates as pharmacologically active free drug. Tissue concentrations in lung, liver, and skin substantially exceed plasma concentrations, supporting efficacy in pulmonary and disseminated infections.3
Non-Linear Pharmacokinetics and CYP2C19 (Cytochrome P450 2C19) Polymorphism. Voriconazole exhibits non-linear (saturable) pharmacokinetics, meaning that plasma concentrations do not increase proportionally with dose. This arises because the primary metabolizing enzyme, hepatic cytochrome P450 2C19 (CYP2C19), becomes saturated at therapeutic doses, so modest dose increases produce disproportionately large increases in plasma exposure. CYP2C19 is a genetically polymorphic enzyme with well-characterized allelic variants that result in poor metabolizer (PM), intermediate metabolizer (IM), normal metabolizer (NM), and ultrarapid metabolizer (UM) phenotypes. Poor metabolizers, who carry two loss-of-function CYP2C19 alleles, achieve plasma concentrations four to five times higher than normal metabolizers at the same dose; ultrarapid metabolizers achieve plasma concentrations as much as 50% lower. The frequency of the PM phenotype is approximately 3 to 5% in European and African populations and 15 to 20% in Asian populations, making CYP2C19 genotyping an important consideration when voriconazole is used in diverse patient populations. CYP2C19 is also inhibited by omeprazole and other proton pump inhibitors, further complicating concentration prediction from dose alone.4
CYP (Cytochrome P450) Inhibition and Drug Interactions. Voriconazole is a potent inhibitor of CYP2C19, CYP2C9 (cytochrome P450 2C9), and CYP3A4 (cytochrome P450 3A4), making it one of the most interaction-prone drugs in clinical medicine. Clinically significant interactions include: markedly elevated calcineurin inhibitor (tacrolimus, cyclosporine) concentrations requiring 50 to 67% dose reductions; elevated sirolimus concentrations (combination contraindicated due to extreme exposure amplification); elevated warfarin concentrations requiring close international normalized ratio (INR) monitoring; elevated immunosuppressant and chemotherapy concentrations; and reduced voriconazole concentrations when co-administered with potent CYP inducers such as rifampin (rifampicin), rifabutin, phenytoin, carbamazepine, and long-acting barbiturates (all of which are contraindicated or require extraordinary dose adjustment). St. John's wort is also contraindicated due to CYP3A4 and P-glycoprotein (P-gp) induction. Efavirenz substantially reduces voriconazole plasma concentrations through combined CYP2B6 (cytochrome P450 2B6) and CYP3A4 induction and the combination requires dose adjustment or alternative antifungal selection.4
Antifungal Spectrum. Voriconazole has activity against Aspergillus species including A. fumigatus, A. flavus, A. niger, and A. terreus (the latter being resistant to amphotericin B). It is active against most Candida species, though with reduced activity against C. glabrata and C. krusei relative to the newer echinocandins. Voriconazole also covers Scedosporium apiospermum and Fusarium species, including some isolates resistant to amphotericin B, a clinically critical distinction. The major gap in voriconazole spectrum is the Mucorales order (Rhizopus, Mucor, Lichtheimia, Cunninghamella), against which voriconazole has no meaningful activity. Early clinical reports suggesting voriconazole prophylaxis was associated with breakthrough mucormycosis in hematology patients supported this concern and reinforced the importance of not relying on voriconazole for empirical coverage in settings where Mucorales risk is significant.5
Toxicity. The three dominant toxicities of voriconazole are visual disturbances, hepatotoxicity, and photosensitivity. Visual disturbances occur in 20 to 30% of patients and consist of transient, reversible changes in visual acuity, color perception, and light perception (photopsia) occurring within 30 minutes of each dose and resolving within 30 minutes. They are not associated with permanent visual damage with short-term use, but persistent visual symptoms in patients on long-term voriconazole warrant ophthalmologic evaluation. Hepatotoxicity, manifesting as elevation of liver function tests (LFTs) including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase, occurs in 5 to 15% of patients and is the most common reason for discontinuation. Baseline and periodic LFT (liver function test) monitoring is mandatory. Phototoxic skin reactions, including severe sunburn-like reactions with short sun exposure, occur in patients on long-term voriconazole and are associated in rare cases with squamous cell carcinoma and melanoma with prolonged use, necessitating sun protection counseling. Neuropsychiatric effects including hallucinations, encephalopathy, and delirium have been reported, particularly at supratherapeutic plasma concentrations, highlighting the value of TDM (therapeutic drug monitoring) for both efficacy and toxicity management.3,4
CYP2C19 PM phenotype (15–20% in Asian patients): plasma concentrations 4–5x higher at standard doses — TDM mandatory. Tacrolimus and cyclosporine: reduce dose 50–67% when starting voriconazole; sirolimus: contraindicated. Rifampin, phenytoin, carbamazepine: avoid — these reduce voriconazole concentrations to subtherapeutic levels. IV formulation (SBECD vehicle): switch to oral if CrCl drops below 50 mL/min. Long-term use: sun protection counseling mandatory; annual dermatologic exam for squamous cell carcinoma. No Mucorales coverage: do not use in suspected mucormycosis.
Posaconazole occupies a distinctive clinical niche defined by its role as the preferred antifungal prophylaxis agent in the highest-risk immunocompromised patient populations and by its antifungal spectrum extending to include the Mucorales, a group of mold pathogens against which most other azoles are inactive. Its clinical utility was substantially transformed by the development of delayed-release tablet and intravenous formulations that overcame the erratic absorption characteristics of the original oral suspension.
Formulations and Pharmacokinetics. Three posaconazole formulations are available: oral suspension (40 mg/mL), delayed-release (DR) tablets (100 mg), and an intravenous solution formulated with SBECD (sulfobutylether-beta-cyclodextrin) as a solubilizing vehicle. The oral suspension is highly dependent on food intake and gastric acidity for absorption; administration with a high-fat meal increases AUC (area under the concentration-time curve) by approximately fourfold compared to fasting, and the suspension must be administered four times daily with meals or nutritional supplements to achieve reliable plasma concentrations. These absorption requirements make the suspension problematic in patients who are nil by mouth (NPO), have gastroparesis, mucositis, or graft-versus-host disease (GVHD) affecting the GI (gastrointestinal) tract, which are precisely the highest-risk patients for invasive fungal infections. The delayed-release tablet formulation, introduced to address these limitations, provides substantially improved and more consistent oral bioavailability due to a sustained-release pH-dependent polymer matrix that releases posaconazole in the small intestine; it is administered once daily with food and achieves approximately 2.5-fold higher plasma concentrations than the suspension under equivalent conditions. The IV formulation bypasses oral absorption entirely and is the appropriate choice in patients who cannot reliably absorb oral medications.6
Drug Interactions. Posaconazole is a potent inhibitor of CYP3A4 (cytochrome P450 3A4) but does not significantly inhibit CYP2C19 (cytochrome P450 2C19) or CYP2C9 (cytochrome P450 2C9), distinguishing its interaction profile from voriconazole. The most clinically important interactions are marked elevations of calcineurin inhibitor concentrations (tacrolimus and cyclosporine doses must typically be reduced 50 to 75% at posaconazole initiation, with close TDM (therapeutic drug monitoring)), elevated sirolimus and everolimus concentrations, increased exposure to QTc-prolonging drugs including certain antiarrhythmics, elevated concentrations of statin drugs metabolized by CYP3A4, and reduced posaconazole absorption with proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs), which raise gastric pH and reduce dissolution of the suspension formulation. CYP3A4 inducers (rifampin, efavirenz, phenytoin) reduce posaconazole concentrations significantly; the combination with rifampin is contraindicated. In contrast to the IV voriconazole formulation, IV posaconazole carries the same SBECD accumulation concern in renal insufficiency, and switching to or maintaining the oral delayed-release tablet in patients with declining renal function is the preferred strategy.6,7
Antifungal Spectrum. Posaconazole shares the broad Aspergillus spectrum of voriconazole but extends coverage to include the Mucorales (Rhizopus, Mucor, Lichtheimia, Cunninghamella), making it the only oral azole with meaningful anti-Mucorales activity. It also has activity against most Candida species, the dimorphic fungi (Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis), Fusarium species, and dermatophytes. Posaconazole has demonstrated in vitro and limited in vivo activity against Lomentospora prolificans and some rare mold pathogens not covered by other azoles. Candida species with reduced susceptibility to fluconazole and itraconazole, including C. glabrata, typically retain susceptibility to posaconazole at the prophylactic concentrations achieved with standard dosing, though TDM is recommended to verify adequate exposure in patients at high breakthrough risk.7
Prophylaxis Indications and Evidence Base. Posaconazole is the standard of care for antifungal prophylaxis in two high-risk populations with the strongest evidence base. First, patients receiving remission-induction or re-induction chemotherapy for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) have prolonged profound neutropenia and are at high risk for invasive Aspergillus and Mucorales infections. The pivotal randomized controlled trial by Cornely et al. demonstrated that posaconazole suspension significantly reduced the incidence of invasive fungal infections and improved overall survival compared to fluconazole or itraconazole prophylaxis in this population. Second, hematopoietic stem cell transplant (HSCT) recipients with GVHD receiving high-dose immunosuppression represent the second canonical prophylaxis indication; posaconazole suspension reduced invasive fungal infections compared to fluconazole in the randomized trial by Ullmann et al. The delayed-release tablet formulation has become preferred over the suspension in current practice given its superior and more consistent pharmacokinetics. TDM is recommended particularly when the suspension is used or when drug-drug interactions or GI absorption concerns are present, with a target trough concentration above 0.7 mg/L for prophylaxis and above 1.0 mg/L for treatment.6,7
Use delayed-release tablet (300 mg loading dose twice daily on Day 1, then 300 mg once daily) rather than suspension when available — superior and consistent pharmacokinetics. If suspension must be used: 200 mg three times daily with full meals; four times daily in patients with mucositis or GI GVHD. Monitor trough concentration at Day 5–7: target above 0.7 mg/L for prophylaxis. Reduce tacrolimus/cyclosporine dose by 50–75% on initiation and monitor daily. Avoid PPIs with suspension; IV posaconazole bypasses this interaction entirely.
Isavuconazole, approved by the FDA in 2015 for invasive aspergillosis and invasive mucormycosis, represents the most recent addition to the extended-spectrum triazole class. It has garnered rapid adoption in many centers due to its more predictable pharmacokinetics, reduced drug interaction burden compared to voriconazole, absence of the SBECD (sulfobutylether-beta-cyclodextrin) vehicle in its IV formulation, and a tolerability profile that avoids the visual and photosensitivity toxicities that complicate long-term voriconazole use.
Prodrug and Formulation. Isavuconazole is marketed as isavuconazonium sulfate, a water-soluble prodrug that is rapidly hydrolyzed by plasma esterases after oral or IV administration to release the active drug isavuconazole. The prodrug design eliminates the need for SBECD as a solubilizing vehicle in the IV formulation, which is a significant advantage in patients with renal insufficiency who cannot safely receive SBECD-containing IV formulations. Both oral and IV formulations use isavuconazonium sulfate, and the drug may be interchanged between routes without dose adjustment because oral bioavailability is approximately 98% under fasting or fed conditions, with no significant food effect. This is pharmacokinetically superior to both voriconazole (requires fasting) and posaconazole suspension (requires high-fat meal).8
Pharmacokinetics. Isavuconazole has linear (first-order) pharmacokinetics at clinical doses, in contrast to the non-linear pharmacokinetics of voriconazole. This means plasma concentrations increase proportionally with dose, making pharmacokinetic prediction from dose more reliable. The volume of distribution is large (approximately 450 L), reflecting extensive tissue distribution. Protein binding is greater than 99%, predominantly to albumin. The drug is primarily metabolized by CYP3A4 (cytochrome P450 3A4) and CYP3A5 (cytochrome P450 3A5), with secondary contributions from uridine diphosphate glucuronosyltransferase (UGT) enzymes. The terminal half-life is approximately 130 hours (five to six days), making it the longest-acting of the extended-spectrum triazoles and allowing once-daily maintenance dosing after a loading regimen. The prolonged half-life means steady-state concentrations are not achieved for approximately three weeks without loading, making a loading dose essential to achieve therapeutic concentrations rapidly in acute invasive infection.8
Drug Interactions. Isavuconazole inhibits CYP3A4, though with somewhat lower potency than voriconazole or posaconazole, and also inhibits P-glycoprotein (P-gp) and the drug transporter BCRP (breast cancer resistance protein). Calcineurin inhibitor concentrations are elevated by isavuconazole, but to a lesser degree than with voriconazole or posaconazole, and the magnitude of tacrolimus dose reduction required is often smaller. Sirolimus concentrations are still substantially elevated and the combination requires careful TDM (therapeutic drug monitoring). Strong CYP3A4 inducers (rifampin, carbamazepine, long-acting barbiturates) reduce isavuconazole concentrations significantly and are contraindicated. Of note, isavuconazole shortens the QTc interval (rather than prolonging it, as most other azoles and many other antifungals do), which has both clinical advantages (safer in patients with baseline QTc prolongation) and diagnostic implications (QTc shortening in a patient whose ECG (electrocardiogram) was normal may indicate supratherapeutic isavuconazole concentrations). Lopinavir and other HIV (human immunodeficiency virus) protease inhibitors inhibit CYP3A4 and increase isavuconazole exposure; coadministration requires TDM.8,9
Spectrum and Clinical Efficacy. The antifungal spectrum of isavuconazole encompasses Aspergillus species (including the rare but AmB-resistant A. terreus), Candida species (with activity similar to voriconazole), the Mucorales (Rhizopus, Mucor, Lichtheimia), and the dimorphic fungi. The SECURE (Safety and Efficacy of Isavuconazole vs. Voriconazole) trial, a randomized double-blind non-inferiority study comparing isavuconazole with voriconazole for primary treatment of invasive mold disease (predominantly Aspergillus), demonstrated non-inferior all-cause mortality at Day 42 (isavuconazole 19.0% vs. voriconazole 20.0%) and a significantly better tolerability profile, with fewer visual adverse effects, hepatotoxicity, and skin reactions in the isavuconazole arm. The VITAL (Voriconazole vs. Amphotericin B for Invasive Aspergillosis, Later Amended to Include Mucormycosis) trial, a single-arm study without a randomized comparator, examined isavuconazole in invasive mucormycosis and reported outcomes comparable to a matched historical cohort treated with amphotericin B, supporting FDA approval for mucormycosis as well. Isavuconazole lacks reliable activity against Scedosporium prolificans and some rare non-fumigatus Aspergillus species, and susceptibility testing is recommended for these organisms.9
Prefer isavuconazole over voriconazole when: (1) renal insufficiency precludes IV voriconazole (SBECD accumulation) and oral voriconazole absorption is unreliable; (2) baseline QTc prolongation makes further QTc-prolonging drugs hazardous; (3) patient is at high risk for voriconazole photosensitivity or long-term skin toxicity; (4) suspected or confirmed mucormycosis where oral azole coverage of Mucorales is desired; (5) simpler pharmacokinetics and no food effect are operationally important. Voriconazole retains advantages in CNS aspergillosis (higher CSF penetration data) and when lower drug cost is a priority where generic voriconazole is available.
Azole resistance in clinically important mold and yeast pathogens has become an increasingly significant problem over the past two decades, driven by mechanisms that differ between organisms and by the emergence of environmentally acquired azole-resistant Aspergillus fumigatus strains that represent a global public health challenge. Therapeutic drug monitoring complements resistance surveillance by ensuring adequate drug exposure in the individual patient, and its indications, methods, and target concentrations for the extended-spectrum azoles are now sufficiently well established to guide routine clinical practice.
ERG11 (Sterol 14-Alpha-Demethylase Gene) Mutations in Candida. In Candida species, azole resistance most commonly arises through mutations in ERG11, the gene encoding the fungal CYP51 (lanosterol 14-alpha-demethylase) target enzyme. Point mutations in ERG11 reduce the binding affinity of azoles for the enzyme active site without completely abolishing catalytic function, allowing ergosterol biosynthesis to continue at a reduced rate while the azole fails to achieve inhibitory concentrations at the target. Different mutations confer different degrees and patterns of cross-resistance among azoles: some mutations reduce susceptibility primarily to fluconazole while maintaining susceptibility to the extended-spectrum agents, whereas others confer broader cross-resistance. ERG11 mutations are often accompanied by upregulation of drug efflux pumps encoded by the CDR1 (Candida drug resistance 1), CDR2 (Candida drug resistance 2), and MDR1 (multidrug resistance 1) genes, which actively export azoles from the fungal cell and amplify the resistance phenotype. The combination of target site mutation and active efflux represents the highest level of azole resistance seen in clinical Candida isolates.10
Cyp51A Alterations and Environmental Resistance in Aspergillus. In Aspergillus fumigatus, azole resistance mechanisms center on the cyp51A gene encoding the fungal CYP51 target. The most clinically and epidemiologically important resistance mechanism is a 34-base-pair tandem repeat insertion in the cyp51A promoter combined with a leucine-to-histidine substitution at codon 98. This combined mutation confers high-level pan-azole resistance (resistant to voriconazole, itraconazole, and posaconazole simultaneously) and has been detected in environmental soil samples, compost, and flower bulbs across Europe, Asia, Africa, and North America. The environmental origin is attributed to selective pressure from agricultural use of demethylase-inhibitor (DMI) fungicides, which share the same CYP51 target as medical azoles. Patients who develop this resistance pattern-positive invasive aspergillosis are predominantly immunocompromised individuals who have not received prior medical azole therapy, indicating environmental azole exposure as the primary resistance driver. A second major mutation, TR46/Y121F/T289A (a 46-base-pair tandem repeat with dual amino acid substitutions), confers voriconazole-specific resistance without cross-resistance to itraconazole. Azole-resistant Aspergillus infections carry a significantly higher mortality than susceptible infections, and initial resistance testing is now recommended for all invasive Aspergillus isolates in centers where resistance prevalence exceeds approximately 5 to 10%.1011
Therapeutic Drug Monitoring: Rationale and Methods. TDM (therapeutic drug monitoring) measures drug concentrations in patient plasma to verify that dosing achieves target exposure ranges associated with efficacy while avoiding supratherapeutic concentrations associated with toxicity. The rationale for TDM is strongest when a drug has a narrow therapeutic index, significant interpatient pharmacokinetic variability, non-linear pharmacokinetics, or demonstrable exposure-response relationships for both efficacy and toxicity. Voriconazole satisfies all four criteria: the coefficient of variation for plasma concentrations at standard doses exceeds 80%, driven by CYP2C19 (cytochrome P450 2C19) genotype, comedications, severity of illness, and hepatic function. For voriconazole, trough concentrations (Cmin, measured immediately before the next dose) should be obtained at steady state, which is typically achieved after 5 to 7 days of standard dosing. The target trough range is 1 to 5.5 mg/L: concentrations below 1 mg/L are associated with treatment failure, and concentrations above 5.5 mg/L are associated with neurotoxicity, hepatotoxicity, and visual adverse effects. Some guidelines suggest an upper target of 4.0 to 5.0 mg/L given the toxicity risk at higher concentrations.4
TDM for Posaconazole and Isavuconazole. Posaconazole TDM is particularly important when the oral suspension is used, given the highly variable absorption of that formulation. Target trough concentrations for posaconazole are above 0.7 mg/L for prophylaxis and above 1.0 mg/L (with some authorities recommending above 1.25 to 1.5 mg/L) for treatment of invasive infection. For prophylaxis with the delayed-release tablet, TDM is less critical given the more consistent pharmacokinetics of that formulation but remains advisable in patients with GI (gastrointestinal) dysfunction, significant drug-drug interactions, or documented breakthrough infections. Isavuconazole TDM is performed in some centers given the drug's long half-life and the potential for interactions that alter exposure, though its linear pharmacokinetics reduce the urgency compared to voriconazole. There is no established consensus target trough range for isavuconazole in invasive infection at the time of current evidence; monitoring is primarily directed at detecting very low concentrations in patients receiving CYP3A4 (cytochrome P450 3A4) inducers or at identifying supratherapeutic concentrations in patients receiving strong CYP3A4 inhibitors.9,11
Voriconazole trough: target 1.0–5.5 mg/L; below 1.0 mg/L correlates with treatment failure; above 5.5 mg/L correlates with neurotoxicity and hepatotoxicity. Obtain at Day 5–7 of therapy. Posaconazole trough (suspension or IV): target above 0.7 mg/L for prophylaxis; above 1.0 mg/L (ideally 1.25–1.5 mg/L) for treatment. Posaconazole delayed-release tablet: TDM still advisable in high-risk patients but concentrations more predictable. Isavuconazole: TDM not routinely standardized; check if patient on CYP3A4 inducers or inhibitors or breakthrough infection despite therapy.
Translating the pharmacological differences among voriconazole, posaconazole, and isavuconazole into prescribing decisions requires integrating spectrum, pharmacokinetics, toxicity, interaction profile, and formulation practicalities with the specific clinical scenario. The following sections synthesize the preceding pharmacological data into a decision framework organized by indication.
Invasive Aspergillosis. Voriconazole and isavuconazole are both established as first-line therapy for invasive pulmonary aspergillosis (IPA) in immunocompromised hosts. The head-to-head SECURE (Safety and Efficacy of Isavuconazole vs. Voriconazole) trial established non-inferiority of isavuconazole versus voriconazole in all-cause mortality and provided the evidence base for isavuconazole as an alternative first-line agent. In centers where generic voriconazole is widely available, cost considerations may favor voriconazole. In patients with renal insufficiency (CrCl below 50 mL/min) who cannot receive IV voriconazole due to SBECD (sulfobutylether-beta-cyclodextrin) accumulation and in whom oral absorption is questionable, isavuconazole IV (no SBECD) or oral (near-complete bioavailability regardless of food) is a more practical choice. For CNS (central nervous system) aspergillosis, voriconazole remains the preferred agent on the basis of higher published CSF (cerebrospinal fluid) penetration data and extensive clinical experience; isavuconazole is a reasonable alternative in patients who cannot tolerate voriconazole. Posaconazole is not considered first-line for primary treatment of established invasive aspergillosis and is reserved primarily for salvage therapy in refractory cases.5,9
Invasive Mucormycosis. Both posaconazole and isavuconazole have demonstrated activity against Mucorales and are approved for mucormycosis treatment; voriconazole has no meaningful Mucorales activity and should not be used. Liposomal amphotericin B (L-AmB) remains the preferred primary treatment for mucormycosis given its superior fungicidal activity and the larger evidence base. However, isavuconazole and posaconazole (delayed-release tablet or IV) are appropriate for patients who cannot tolerate L-AmB or as step-down oral therapy following initial L-AmB induction once clinical stabilization is achieved. The practice of oral step-down with an extended-spectrum azole after AmB induction has become standard in many centers managing mucormycosis in hematology and transplant patients.7,9
Antifungal Prophylaxis. Posaconazole is the preferred agent for antifungal prophylaxis in high-risk populations: AML/MDS (acute myeloid leukemia/myelodysplastic syndrome) patients receiving remission-induction chemotherapy and HSCT (hematopoietic stem cell transplant) recipients with GVHD (graft-versus-host disease) requiring high-dose corticosteroids or calcineurin inhibitors. The evidence base from randomized trials is strongest for posaconazole in these settings. Voriconazole prophylaxis has been used in some centers for allogeneic HSCT recipients but is not approved for this indication by the FDA and carries higher drug interaction burden. Isavuconazole has not been studied in large randomized prophylaxis trials and cannot be recommended as a standard prophylaxis agent on current evidence. Fluconazole remains appropriate for prophylaxis in lower-risk settings (autologous HSCT, surgical ICU) where the primary concern is Candida rather than molds.6,7
Managing Drug Interactions in Transplant Patients. Extended-spectrum azoles are most commonly used in allogeneic HSCT and solid organ transplant recipients, populations who are already receiving complex multi-drug regimens. Calcineurin inhibitor management is the most critical interaction to handle systematically. When starting any extended-spectrum azole, the calcineurin inhibitor dose must be proactively reduced before the azole reaches steady state, not reactively after the calcineurin inhibitor trough rises. A pragmatic approach is to reduce tacrolimus to approximately one-third of its usual dose when starting voriconazole or posaconazole, and to approximately half its usual dose with isavuconazole, then titrate based on daily tacrolimus troughs for the first week. Failure to preemptively reduce calcineurin inhibitor doses when azoles are started is a recognized cause of calcineurin inhibitor nephrotoxicity and neurotoxicity in transplant recipients. Sirolimus is contraindicated with voriconazole and posaconazole and requires careful TDM (therapeutic drug monitoring) with isavuconazole.4,6
Monitoring Parameters. All three extended-spectrum azoles require liver function test monitoring (baseline, then at 2 to 4 weeks, then periodically). Voriconazole additionally requires visual acuity and ophthalmologic monitoring in patients on long-term therapy, and annual dermatologic surveillance for skin malignancy with prolonged use. Posaconazole requires monitoring of QTc interval, particularly when co-administered with other QTc-prolonging drugs, and electrolyte monitoring (hypokalemia potentiates azole-associated QTc prolongation). Isavuconazole requires baseline ECG (QTc shortening is a recognized pharmacodynamic effect) and periodic ECG if supratherapeutic concentrations are suspected. TDM for trough concentrations is mandatory for voriconazole in all patients, advisable for posaconazole (particularly with suspension), and situationally indicated for isavuconazole in high-risk scenarios.4,6,9
All three agents inhibit fungal CYP51 (ERG11/cyp51A); mechanism is fungistatic. Voriconazole: first-line for invasive aspergillosis; non-linear PK; CYP2C19 PM phenotype causes toxicity; visual/hepatic/photosensitivity toxicity; TDM target 1–5.5 mg/L; no Mucorales coverage. Posaconazole: preferred prophylaxis for AML/MDS and GVHD post-HSCT; DR tablet preferred over suspension; TDM target above 0.7 (prophylaxis) or 1.0–1.5 mg/L (treatment); only oral azole with Mucorales activity. Isavuconazole: non-inferior to voriconazole for aspergillosis; linear PK; no SBECD vehicle; approved for mucormycosis; QTc shortening (not prolongation); favorable tolerability profile. TR34/L98H A. fumigatus mutation: pan-azole resistance from environmental DMI fungicide exposure; test all invasive Aspergillus isolates.
White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 1998;11(2):382-402.
doi:10.1128/CMR.11.2.382Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol. 1998;44:343-500.
doi:10.1016/S1054-3589(08)60129-5Saravolatz LD, Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36(5):630-637.
doi:10.1086/367933Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56(9):4793-4799.
doi:10.1128/AAC.00626-12Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60.
doi:10.1093/cid/ciw326Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348-359.
doi:10.1056/NEJMoa061094Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335-347.
doi:10.1056/NEJMoa061098Schmitt-Hoffmann A, Roos B, Maares J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):286-293.
doi:10.1128/AAC.50.1.286-293.2006Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760-769.
doi:10.1016/S0140-6736(15)01159-9Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002;2(2):73-85.
doi:10.1016/S1473-3099(02)00181-0Arendrup MC, Patterson TF. Multidrug-resistant Aspergillus versus other pathogens: are we heading toward a pan-azole-resistant world? Med Mycol. 2017;55(1):3-9.
doi:10.1093/mmy/myw116